MX2020002500A - Adn de extremo cerrado modificado (adnec). - Google Patents
Adn de extremo cerrado modificado (adnec).Info
- Publication number
- MX2020002500A MX2020002500A MX2020002500A MX2020002500A MX2020002500A MX 2020002500 A MX2020002500 A MX 2020002500A MX 2020002500 A MX2020002500 A MX 2020002500A MX 2020002500 A MX2020002500 A MX 2020002500A MX 2020002500 A MX2020002500 A MX 2020002500A
- Authority
- MX
- Mexico
- Prior art keywords
- cedna
- cedna vectors
- linear
- vectors
- ended dna
- Prior art date
Links
- 239000013598 vector Substances 0.000 abstract 4
- 230000014509 gene expression Effects 0.000 abstract 3
- 108700019146 Transgenes Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/60—Vectors comprising a special translation-regulating system from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556281P | 2017-09-08 | 2017-09-08 | |
| US201762556324P | 2017-09-08 | 2017-09-08 | |
| US201762556331P | 2017-09-08 | 2017-09-08 | |
| US201762556319P | 2017-09-08 | 2017-09-08 | |
| US201762556335P | 2017-09-08 | 2017-09-08 | |
| US201762556329P | 2017-09-08 | 2017-09-08 | |
| PCT/US2018/049996 WO2019051255A1 (en) | 2017-09-08 | 2018-09-07 | CLOSED-ENDED DNA (CEDNA) MODIFIED |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002500A true MX2020002500A (es) | 2020-09-17 |
Family
ID=65635235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002500A MX2020002500A (es) | 2017-09-08 | 2018-09-07 | Adn de extremo cerrado modificado (adnec). |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200283794A1 (enExample) |
| EP (1) | EP3678710A4 (enExample) |
| JP (3) | JP2020532981A (enExample) |
| KR (1) | KR20200051011A (enExample) |
| CN (1) | CN111132699A (enExample) |
| AU (1) | AU2018327348A1 (enExample) |
| BR (1) | BR112020004151A2 (enExample) |
| CA (1) | CA3075168A1 (enExample) |
| IL (1) | IL272797A (enExample) |
| MA (1) | MA50100A (enExample) |
| MX (1) | MX2020002500A (enExample) |
| PH (1) | PH12020500465A1 (enExample) |
| SG (1) | SG11202000698SA (enExample) |
| UA (1) | UA129010C2 (enExample) |
| WO (1) | WO2019051255A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CN105939767B (zh) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | 具有双声电泳腔的声电泳装置 |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| MX2020001593A (es) | 2017-08-09 | 2020-07-13 | Bioverativ Therapeutics Inc | Moleculas de acido nucleico y usos de las mismas. |
| JP2021505159A (ja) * | 2017-12-06 | 2021-02-18 | ジェネレーション バイオ カンパニー | 修飾型閉端ｄｎａ（ｃｅｄｎａ）を使用する遺伝子編集 |
| CN114900773A (zh) | 2017-12-14 | 2022-08-12 | 弗洛设计声能学公司 | 声泳系统及其操作方法、控制声换能器及声学系统的方法 |
| AU2019221642A1 (en) * | 2018-02-14 | 2020-07-09 | Generation Bio Co. | Non-viral DNA vectors and uses thereof for antibody and fusion protein production |
| JP7602454B2 (ja) | 2018-08-09 | 2024-12-18 | バイオベラティブ セラピューティクス インコーポレイテッド | 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用 |
| WO2020097417A1 (en) * | 2018-11-09 | 2020-05-14 | Generation Bio Co. | Modified closed-ended dna (cedna) comprising symmetrical modified inverted terminal repeats |
| GB201905651D0 (en) * | 2019-04-24 | 2019-06-05 | Lightbio Ltd | Nucleic acid constructs and methods for their manufacture |
| US20220228171A1 (en) * | 2019-07-17 | 2022-07-21 | Generation Bio Co. | Compositions and production of nicked closed-ended dna vectors |
| WO2021011842A1 (en) * | 2019-07-17 | 2021-01-21 | Generation Bio Co. | Synthetic production of single-stranded adeno associated viral dna vectors |
| WO2021030745A1 (en) * | 2019-08-15 | 2021-02-18 | The Children's Hospital Of Philadelphia | Combined transgene and intron-derived mirna therapy for treatment of sca1 |
| CN114929205B (zh) * | 2019-09-06 | 2024-09-03 | 世代生物公司 | 包括末端封闭式dna和可切割脂质的脂质纳米颗粒组合物及其使用方法 |
| WO2021055760A1 (en) | 2019-09-18 | 2021-03-25 | Intergalactic Therapeutics, Inc. | Synthetic dna vectors and methods of use |
| WO2021072031A1 (en) * | 2019-10-11 | 2021-04-15 | Insideoutbio, Inc. | Methods and compositions for the manufacture and use of circular dna encoded therapeutics for genetic disorders and other diseases |
| WO2021169167A1 (en) * | 2020-02-29 | 2021-09-02 | Nanjing GenScript Biotech Co., Ltd. | Method for treating coronavirus infections |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| IL296660A (en) * | 2020-03-24 | 2022-11-01 | Generation Bio Co | Non-viral DNA vectors and their use for therapeutic expression of factor ix |
| IL296662A (en) * | 2020-03-24 | 2022-11-01 | Generation Bio Co | Non-viral dna vectors and uses thereof for expressing gaucher therapeutics |
| CN115968280A (zh) * | 2020-05-18 | 2023-04-14 | 世代生物公司 | 新型脂质及其纳米颗粒组合物 |
| MX2023001109A (es) | 2020-07-27 | 2023-04-24 | Anjarium Biosciences Ag | Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas. |
| AU2021330936A1 (en) | 2020-08-23 | 2023-05-04 | Bioverativ Therapeutics Inc. | MODIFIED BACULOVIRUS SYSTEM FOR IMPROVED PRODUCTION OF CLOSED-ENDED DNA (ceDNA) |
| US20220243201A1 (en) * | 2020-08-23 | 2022-08-04 | Bioverativ Therapeutics Inc. | Engineered itr sequences and methods of use |
| CA3191743A1 (en) * | 2020-09-16 | 2022-03-24 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing fviii therapeutics |
| MX2023003019A (es) * | 2020-09-16 | 2023-05-08 | Generation Bio Co | Vectores de adn de extremo cerrado y usos de estos para expresar fenilalanina hidroxilasa (pah). |
| GB202014751D0 (en) * | 2020-09-18 | 2020-11-04 | Lightbio Ltd | Targeting vector |
| WO2022198025A2 (en) * | 2021-03-19 | 2022-09-22 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing pfic therapeutics |
| WO2022232029A2 (en) * | 2021-04-26 | 2022-11-03 | University Of Florida Research Foundation, Incorporated | Synthetic aav vectors for repeated delivery of therapeutic genes |
| JP2024515788A (ja) * | 2021-04-27 | 2024-04-10 | ジェネレーション バイオ カンパニー | 治療抗体を発現する非ウイルスｄｎａベクター及びその使用 |
| US20240216535A1 (en) * | 2021-04-27 | 2024-07-04 | Generation Bio Co. | Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof |
| EP4333886A4 (en) * | 2021-05-07 | 2025-11-12 | Generation Bio Co | NON-VIRAL DNA VECTORS FOR VACCINE ADMINISTRATION |
| WO2022236016A1 (en) * | 2021-05-07 | 2022-11-10 | Generation Bio Co. | Lyophilized non-viral dna vector compositions and uses thereof |
| WO2023069948A1 (en) * | 2021-10-18 | 2023-04-27 | Flagship Pioneering Innovations Vii, Llc | Dna compositions and related methods |
| EP4493212A1 (en) | 2022-03-14 | 2025-01-22 | Generation Bio Co. | Heterologous prime boost vaccine compositions and methods of use |
| CN117802161A (zh) * | 2022-06-30 | 2024-04-02 | 苏州吉恒基因科技有限公司 | 精准重组腺相关病毒载体及其用途 |
| WO2024040222A1 (en) * | 2022-08-19 | 2024-02-22 | Generation Bio Co. | Cleavable closed-ended dna (cedna) and methods of use thereof |
| JP2026508358A (ja) | 2023-03-02 | 2026-03-10 | クリスタル バイオテック インコーポレイテッド | がん治療用のインターロイキン－２およびインターロイキン－１２ |
| US11891617B1 (en) * | 2023-03-27 | 2024-02-06 | Genecraft Inc. | Modified complex platform of adeno-associated virus with improved rate of expression of loaded genes and reduced genotoxicity |
| US11993783B1 (en) * | 2023-03-27 | 2024-05-28 | Genecraft Inc. | Nucleic acid molecule comprising asymmetrically modified ITR for improving expression rate of inserted gene, and use thereof |
| US11767541B1 (en) * | 2023-03-27 | 2023-09-26 | Genecraft, Inc. | Adeno-associated virus complex with improved expression of RUNX3 gene and uses for preventing or treating KRAS mutated lung cancer |
| WO2024220969A2 (en) * | 2023-04-21 | 2024-10-24 | Arizona Board Of Regents On Behalf Of Arizona State University | Novel transmembrane sensors and method of characterization for lysis-free detection of intracellular targets |
| CN122341729A (zh) * | 2023-11-30 | 2026-07-03 | 赛诺菲 | 末端封闭的dna分子的纯化 |
| WO2026085495A1 (en) | 2024-10-18 | 2026-04-23 | Generation Bio Co. | Synthetic partially single-stranded nucleic acid compositions and uses and methods therefor |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050019824A1 (en) * | 1994-03-08 | 2005-01-27 | Human Genome Sciences, Inc. | Fibroblast Growth Factor-10 |
| US20050026838A1 (en) * | 1995-06-05 | 2005-02-03 | Human Genome Sciences, Inc. | Fibroblast Growth Factor-13 |
| DE10066104A1 (de) * | 2000-09-08 | 2003-01-09 | Medigene Ag | Wirtszellen zur Verpackung von rekombinantem Adeno-assoziiertem Virus (rAAV), Verfahren zu ihrer Herstellung und deren Verwendung |
| US20060166363A1 (en) * | 2004-01-27 | 2006-07-27 | Sergei Zolotukhin | Modified baculovirus expression system for production of pseudotyped rAAV vector |
| WO2008016391A2 (en) * | 2006-01-31 | 2008-02-07 | The Board Of Trustees Of The Leland Stanford Junior University | Self-complementary parvoviral vectors, and methods for making and using the same |
| EP2500434A1 (en) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| EP2866826B1 (en) * | 2012-06-27 | 2025-08-06 | Meiragtx UK II Limited | Combination for treating an inflammatory disorder |
| CN104087613B (zh) * | 2014-06-30 | 2017-08-29 | 中国科学院苏州生物医学工程技术研究所 | 基于aav‑itr的基因表达微载体及其构建方法和应用 |
| IL297238B2 (en) * | 2016-01-15 | 2024-08-01 | American Gene Tech Int Inc | Methods and preparations for gamma-delta T-cell activation |
| IL261524B2 (en) * | 2016-03-03 | 2023-10-01 | Univ Massachusetts | End-capped linear double-stranded DNA for non-viral gene transfer |
-
2018
- 2018-09-07 CA CA3075168A patent/CA3075168A1/en active Pending
- 2018-09-07 CN CN201880058155.7A patent/CN111132699A/zh active Pending
- 2018-09-07 WO PCT/US2018/049996 patent/WO2019051255A1/en not_active Ceased
- 2018-09-07 AU AU2018327348A patent/AU2018327348A1/en not_active Abandoned
- 2018-09-07 BR BR112020004151-3A patent/BR112020004151A2/pt not_active Application Discontinuation
- 2018-09-07 US US16/644,568 patent/US20200283794A1/en not_active Abandoned
- 2018-09-07 SG SG11202000698SA patent/SG11202000698SA/en unknown
- 2018-09-07 JP JP2020512843A patent/JP2020532981A/ja active Pending
- 2018-09-07 UA UAA202000594A patent/UA129010C2/uk unknown
- 2018-09-07 MA MA050100A patent/MA50100A/fr unknown
- 2018-09-07 MX MX2020002500A patent/MX2020002500A/es unknown
- 2018-09-07 EP EP18854941.4A patent/EP3678710A4/en active Pending
- 2018-09-07 KR KR1020207009737A patent/KR20200051011A/ko not_active Ceased
-
2020
- 2020-02-20 IL IL272797A patent/IL272797A/en unknown
- 2020-03-06 PH PH12020500465A patent/PH12020500465A1/en unknown
-
2022
- 2022-11-02 JP JP2022176371A patent/JP2022190081A/ja active Pending
-
2024
- 2024-10-28 JP JP2024189111A patent/JP2025010253A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| UA129010C2 (uk) | 2024-12-25 |
| MA50100A (fr) | 2020-07-15 |
| RU2020109904A (ru) | 2021-10-08 |
| CA3075168A1 (en) | 2019-03-14 |
| EP3678710A1 (en) | 2020-07-15 |
| PH12020500465A1 (en) | 2021-01-25 |
| JP2022190081A (ja) | 2022-12-22 |
| CN111132699A (zh) | 2020-05-08 |
| NZ761178A (en) | 2024-05-31 |
| US20200283794A1 (en) | 2020-09-10 |
| KR20200051011A (ko) | 2020-05-12 |
| JP2025010253A (ja) | 2025-01-20 |
| EP3678710A4 (en) | 2021-06-09 |
| AU2018327348A1 (en) | 2020-02-20 |
| IL272797A (en) | 2020-04-30 |
| SG11202000698SA (en) | 2020-03-30 |
| BR112020004151A2 (pt) | 2020-09-08 |
| JP2020532981A (ja) | 2020-11-19 |
| WO2019051255A1 (en) | 2019-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500465A1 (en) | Modified closed-ended dna (cedna) | |
| PH12020550771A1 (en) | Gene editing using a modified closed-ended dna (cedna) | |
| MX2021004842A (es) | Adn de extremo cerrado (ceadn) modificado que comprende repeticiones terminales invertidas modificadas simetricas. | |
| SA518391294B1 (ar) | التحرير المتعدد للجينوم | |
| PH12021550904A1 (en) | Novel crispr/cas12f enzyme and system | |
| WO2015168547A3 (en) | In vivo gene engineering with adenoviral vectors | |
| MX2025014318A (es) | Vector de adenovirus de chimpance util para la administracion de neoantigenos | |
| MX2021003188A (es) | Composiciones y métodos para la manufactura de vectores de terapia génica. | |
| SA517381912B1 (ar) | "عناصر تنظيمية معدلة بعد الانتساخ لعلاج الالتهاب الكبدي pre | |
| WO2016183438A8 (en) | Self-targeting genome editing system | |
| EP3597760A3 (en) | Adeno-associated virus vector | |
| MX2022003994A (es) | Produccion de oligosacaridos de leche humana en huespedes microbianos con importacion/exportacion dise?ada. | |
| EP4576103A3 (en) | Neoantigen identification using hotspots | |
| MX2020004149A (es) | Variantes de desoxirribonucleasa (dnasa). | |
| WO2021055459A8 (en) | Highly efficient dna base editors mediated by rna-aptamer recruitment for targeted genome modification and uses thereof | |
| MX2017014125A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
| GB2569734A (en) | RNA-guided nucleic acid modifying enzymes and methods of use thereof | |
| MX391311B (es) | Acidos nucleicos modificados dirigidos a acidos nucleicos. | |
| SG10201809075XA (en) | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues | |
| MX2018010172A (es) | Sistema vector inmunoestimulante novedoso. | |
| NZ609903A (en) | Expression vector for high level expression of recombinant proteins | |
| EP3760713A3 (en) | Lipase variants and polynucleotides encoding same | |
| EP3964575A3 (en) | Alpha-amylase variants and polynucleotides encoding same | |
| EP3950939A3 (en) | Lipase variants and polynucleotides encoding same | |
| MX2017001824A (es) | Mutaciones en proteinas del grupo hierro-azufre que mejoran la utilizacion de xilosa. |